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Summary The characteristics of cell death were investigated after exposure of CCRF-CEM.f2 cells to five
drugs over a broad concentration range; these were the glucocorticoid dexamethasone (DXM), the mitotic
inhibitor vincristine (VIN) and three antimetabolites, methotrexate (MTX), 5'-fluoro-2'-deoxyuridine (FUdR)
and 5'-fluorouracil (5-FU). Drug-treated cells were monitored for cell death mechanisms at different times by
examining the pattern of DNA degradation, cell morphology and flow cytometric profile, together with effects
on cell growth over 72 h. At growth-inhibitory drug concentrations, the first changes were cell cycle perturba-
tions detectable after 4-6 h of drug exposure. The appearance of features characteristic of apoptotic cell death
was noted after all drug treatments in the CCRF-CEM.f2 cell line, but the pattern and kinetics varied
considerably. VIN induced apoptotic changes by 12 h, while DXM treatment caused apoptosis only after 48 h.
Both MTX and FUdR induced morphological changes characteristic of apoptosis at least 24 h before
internucleosomal DNA cleavage, which was detectable only after 48 h. In contrast, 5-FU did not cause
internucleosomal DNA cleavage by 48 h at any concentration, despite the presence of morphologically
apoptotic cells 24 h earlier. These data suggest that disruption of the cell cycle caused by drug treatment may
be the common trigger initiating the drug-specific apoptotic sequence of dying cells.
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Anti-cancer drug treatment of many cultured cells induces
cell death by apoptosis (for reviews see Dive and Hickman,
1991; Hickman, 1992). How such a wide variety of drugs
induce the apoptotic process is unknown, but knowledge of
the sequence of molecular events causing apoptotic cell death
may have implications for optimal cancer chemotherapy.
During the apoptotic process, the cell participates in its
own 'suicide' by the activation of a cascade of events that
leads ultimately to nuclear fragmentation, DNA degradation
and the formation of apoptotic bodies, which in turn can be
engulfed by macrophages or surrounding cells (Kerr et al.,
1987; Wyllie, 1987; Arends et al., 1991). Apoptosis is distinct
from necrotic cell death, which is characterised by increased
membrane permeability and collapse of cellular homeostasis
(Wyllie, 1980). The apoptotic mode of cell death is now
usually defined by morphological criteria together with inter-
nucleosomal DNA digestion (Russell et al., 1992). Mor-
phologically, apoptosis is characterised by the appearance of
condensed chromatin, which marginises to the nuclear mem-
brane (Wyllie et al., 1980). The characteristic discretely
digested DNA is recognised as a ladder pattern on DNA
agarose gels (Wyllie, 1980; Arends et al., 1990). Recently,
flow cytometry has been used to distinguish apoptotic and
necrotic cell populations (Dive et al., 1992; Hotz et al., 1992;
Huschtscha et al., 1994). The appearance of a subpopulation
of small cells that has increased cellular granularity defines
cells undergoing the apoptotic process.
Several studies have indicated the importance of examining
cytotoxic mechanisms using at least two criteria, most com-
monly cell morphology with DNA gel electrophoresis (Mc-
Dougall et al., 1990; Russell et al., 1992; Catchpoole and
Stewart, 1993; Huschtscha et al., 1995). The results are some-
times discordant. For instance, after treatment of CCRF-
CEM.f2 cells with 5'-fluorouracil (5-FU) (10-' and 10-2 M),
the nuclei developed apoptotic morphology but no DNA
ladders appeared on agarose gels.
In an attempt to unravel the apoptotic process, we have
used three methods to monitor CCRF-CEM.f2 cells after
exposure to five different drugs over a broad concentration
range. The mode of cell death was studied at particular time
intervals by morphological studies, DNA gel electrophoresis
and by flow cytometry. The drug effects were also assessed by
monitoring growth over a 3 day period. The drugs used were
dexamethasone (DXM; a glucocorticoid), vincristine (VIN; a
mitotic inhibitor), methotrexate (MTX; an inhibitor of
dihydrofolate reductase) and the fluoropyrimidines, 5'-fluoro-
2'-deoxyuridine (FUdR) and 5-FU. The first changes seen
after drug treatment were cell cycle perturbations detected
using flow cytometric methods. Morphological alterations
typical of apoptosis appeared later and in most cases
preceded the appearance of DNA ladders. Each drug showed
its own pattern of changes in the CCRF-CEM.f2 cell line as
judged by the above criteria.
Materials and methods
Cell culture
The acute leukaemic T-lymphocyte cell line CCRF-CEM.f2
(Foley et al., 1965) was grown in RPMI-1640 medium (ICN,
Biomedicals, Irvine, UK) supplemented with 10% fetal calf
serum, 40 fig ml-' gentamycin, 20 mM Hepes and 2 mM
glutamine, in a closed system at 37°C. The cells were
routinely screened for mycoplasma contamination by using
the Gen-Probe Rapid Detection System (Gen-Probe, La
Jolla, CA, USA) and the cultures were mycoplasma negative.
Cytotoxic drugs
DXM, 5-FU and FUdR were obtained from Sigma, St
Louis, MO, USA. VIN and MTX were obtained from David
Bull Laboratories, Mulgrave, Australia.
Drug treatment
Cells in log-phase of growth were suspended at a density of
105 cells ml-' and 24 h later the appropriate concentrations
of each drug were added. At particular time intervals after
drug addition the cells were counted and their viability deter-
mined by trypan blue exclusion. Drug-induced growth inhibi-
tion in these experiments is defined as <80% growth com-
pared with control cells.
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CCRF-CEM.f2 cells were seeded at a density of 105 cells per
well (24-well tray, Costar, Cambridge, MA, USA). After 24 h
the appropriate concentration of each drug was added and
thereafter the cells were counted in triplicate every 24 h over
a 3 day period using a Coulter Counter (Model ZBI, Coulter
Electronics, Harpenden, UK).
Morphological studies
The morphology of control and drug-treated cells was
studied by staining the cells with the fluorescent dye, Hoescht
(Ho33342). Apoptotic cells were recognised by the appear-
ance of condensed nuclear chromatin or of fragmented
nuclei. Approximately 5 x 106 drug-treated cells were washed
in phosphate-buffered saline (PBS) and resuspended in
5 jsg ml-' Ho33342 for 30 min at 37°C. Stained cells were
viewed and photographed with a Leitz Orthoplan fluorescent
microscope. At least a total of 200 cells were scored for each
drug treatment by two independent observers.
DNA gel electrophoresis
DNA was isolated using the method of Miller et al. (1988)
with some modifications, (see Huschtscha et al., 1994).
Flow cytometry
Drug-treated cells were analysed by flow cytometry according
to the procedure described previously (Huschtscha et al.,
1994).
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Results
Drug treatment ofCCRF-CEM.J2 cells
CCRF-CEM.f2 cells were exposed to the five drugs over an
extensive concentration range and several criteria were used
to monitor changes at particular time intervals. These criteria
were cell morphology, DNA gel electrophoresis and flow
cytometry together with effects on cell growth.
Figure 1 shows the dose-response curves of CCRF-
CEM.f2 cells at 24, 48 and 72 h and demonstrates that
growth inhibition is time and concentration dependent for all
five drugs. Growth inhibition, that is 80% or less growth
compared with control cells, is apparent after all drug
exposures except for the lowest concentrations of VIN (10-'
M) and DXM (10-', 106 M) (Figure 1). Viability studies
using trypan blue mirrored the data obtained from growth
curves with an increase in drug effect with higher drug con-
centrations and longer exposure (data not shown).
FudR: After 4 h drug exposure at all concentrations, flow
cytometry demonstrated disruption of the cell cycle. At this
time the G2 peak was reduced and cells had accumulated in
the GI phase (an average increase of 18%) at all concentra-
tions (Figure 2a). After 24 h exposure, a subpopulation of
smaller cells was apparent and these had increased granul-
arity, a feature characteristic of apoptotic cells (Huschtscha
et al., 1994; Figure 2b). The appearance of this subpopula-
tion of small cells also coincides with an increase in mor-
phologically apoptotic cells (Figure 3a-d; Table I). These
changes were FUdR concentration dependent with increases
in chromatin condensation and cellular debris being more
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Figure 1 Growth inhibition at different times of CCRF-CEM.f2 cells after drug treatment (a) FUdR, (b) MTX, (c) 5-FU, (d)
DXM and (e) VIN for 0, 24h; M, 48 h; A, 72 h.
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Figure 2 Flow cytometry and forward light scatter (FSC) and side light scatter (SSC) plots of FUdR-treated CCRF-CEM.f2 cells.
(a) 4 h and (b) 24 h.
common at the higher drug concentrations. An accumulation
of cells in the S-phase of the cell cycle was observed for the
lowest concentration of FUdR at 24 h. Features characteris-
tic of necrotic cells were not observed after any treatment.
Internucleosomal DNA cleavage was first detected 48 h after
exposure to FUdR 4 x l0-' and 4 x 10-6 M (Figure 4a,
Table I). Therefore morphological studies and flow cytomet-
ric analysis of FUdR-treated cells detected changes charac-
teristic of apoptotic cells at least 24 h before the appearance
of DNA ladders.
MTX. The kinetics of MTX-induced changes were similar
to those after FUdR exposure. After 4 h an accumulation of
cells in the GI phase of the cell cycle was apparent (data not
shown). Apoptotic features were recognised morphologically
and by flow cytometry 24 h after drug treatment and both
preceded the appearance of internucleosomal DNA cleavage,
which was observed by 48 h at higher concentrations of
MTX (1O-7- 10- M). No DNA degradation, cell cycle
changes or chromatin condensation was visible at the lowest
concentration of MTX (10-8 M) despite significant growth
inhibition (Figure 1).
5-FU: The kinetics of 5-FU effects were similar to those
after FUdR and MTX exposures but the mechanism of cell
death differed. The first changes were the accumulation ofGI
cells (an average increase of 15%) at high concentrations of
5-FU, l0-3_10-2 M (data not shown). At all concentrations
smaller cells with increased granularity were apparent by 11 h
and this subpopulation increased by 24 h in a 5-FU concen-
tration-dependent manner (data not shown). An increase in
chromatin condensation was observed at 24 h only at higher
drug concentrations (Figure 3e-g; Table I). However, by
24 h at the lowest concentration of 5-FU (l0-' M) 'apoptotic'
cells were clearly visible flow cytometrically but only a few
apoptotic cells were detected morphologically at this time.
There was no internucleosomal DNA cleavage on agarose
gels by 48 h despite the presence of apoptotic features by
24 h. At high concentrations of 5-FU only a smear of DNA
(Figure 4b; Table I) was apparent.
DXM: After 10-6_ l0-4 M DXM for 24 h cells were smaller
and growth was reduced (Figure 1). By 48 h at the higher
DXM concentrations both condensation of chromatin and
internucleosomal DNA cleavage were observed (Table I).
Twenty-four hours later, internucleosomal DNA cleavage
was visible at all concentrations and the proportion of cells
with condensed chromatin had markedly increased (Table I).
At this time, many nuclei had fragmented and the cells were
clearly smaller. No significant DNA degradation or chrom-
atin condensation was observed 24 h after DXM treatment.
Flow cytometry was not performed after DXM treatments.
VIN: There were no observable changes at the lowest con-
centration of VIN (10O M) with respqct to cell cycle distribu-
tion, DNA degradation and cell morphology (Figure 5a, b;
Table I). Flow cytometry showed cell cycle changes 4 h after
the addition of the three highest concentrations of VIN
(10-8_10-6 M) with double the proportion of cells accum-
ulated in the G2/M phase compared with control cells (Figure
5a). By 12 h internucleosomal cleavage was visible and after
18 h of drug exposure, the GI peak had disappeared and
subpopulations of both small and large cells with apoptotic
features were apparent flow cytometrically (Figure Sb; Table
I). Cells accumulated in the S-phase of the cell cycle at this
time. Extensive chromatin condensation was apparent by
24 h (Table I), at which time small cells were visible,
although some very large cells exhibiting apoptotic features
were also present. Therefore, both flow cytometry and mor-
phological studies indicate that small and large cells acquire
apoptotic features after VIN treatment. VIN treatment
caused apoptotic changes more quickly than after 5-FU,
FUdR, MTX and DXM treatments.
b a
6
c
U
U
c,,Drug-induced cell death a
LI Huschtscha etal w
57
Figure 3 Morphology of CCRF-CEM.f2 cell stained with Ho33342 and treated with (a and b) 4 x 10-7 M FUdR; (c and d)
4 x 10-6 M FUdR; (e and f) 10-3 M 5-FU; (g and h) 5-FU 10-2 M; for 4 h (a, c, e, g) 24 h (b, d, f, h) (magnification x 400).
Discussion
Cell morphology, DNA agarose gels and flow cytometric
methods were used to monitor the mechanisms of cell death
in CCRF-CEM.f2 cells after exposure to five anti-cancer
drugs. The first changes detected within a few hours of drug
exposure were cell cycle perturbations visible by flow
cytometry. These alterations reflected the reduced growth
rate of drug-treated cells, especially at higher drug concentra-
tions (Figure 1). Longer exposure caused different patterns of
change that were specific for each drug and eventually apop-
totic cell death occurred. The time of appearance of apop-
totic features also differed for each drug studied with VIN
treatment inducing changes typical of apoptotic cell death
most quickly, that is, by 12 h while DXM treatment did not
cause these changes for 48 h for all concentrations studied
(Table 1).
The sequence of events preceding apoptotic cell death
differed for each drug. For VIN and DXM treatments, con-
densation of chromatin and DNA cleavage occurred simul-
taneously after about 12 and 48 h drug exposure respectively
(Table I). However, flow cytometry and morphological
studies identified apoptotic cells 24 h after MTX and FUdR
treatments but internucleosomal cleavage only appeared 24 h
later (Table I). After MTX and FUdR treatments, the
appearance of morphologically apoptotic cells correlated with
the appearance of a new subpopulation of cells detected by
flow cytometry, and without the appearance of DNA deg-
radation (Table I). This observation suggests that flow
cytometry detects DNA loss and chromatin condensation but
internucleosomal DNA cleavage is not recognisable by this
technique.
5-FU caused morphologically recognisable apoptosis as
early as 24 h after drug treatment but internucleosomal DNA
cleavage was not detected at any concentration studied
though a smear of DNA of different sizes was seen by 48 h
(Figures 3e-h, 4b; Table I). In a preliminary study in which
the early events were not investigated we showed that
(10-3 10-2 M) 5-FU treatment of CCRF-CEM.f2 cells for
48 h caused morphological apoptosis without internucleo-ok Drug-induced cell death
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Figure 4 DNA gel electrophoresis of CCRF-CEM.f2 cells after treatment with (a) FUdR; 4 x 10-' M lanes A, E; 4 x 10-7 M lanes
B, F; 4 x 10-6 M lanes C, G; 4 x 10-5 M lanes D, H. For 24 h lanes A, B, C, D and 48 h lanes E, F, G, H. (b) 5-FU, 10-4 M, lanes
A, D, G; 10-3 M, lanes B, E, H; 10-2 M lanes C, F, I. For 6h lanes A, B, C; 24h lanes D, E, F and 48h, lanes G, H, I.
Table I Assessment of CCRF-CEM.f2 cells after drug treatment
Drug
treatment Concentration (M) Chromatin condensation (%) DNA Gels
4h IIh 24h 6h 24h 48h
FUdR 4 x 10-8 3 1 11 - - -
4x 10-7 3 3 27 - - +
4 x 10-6 6 3 49 - - +
4h 24h 12h 24h 48h
MTX 10-8 0 3 - - -
0-7 4 12 - - +
10-6 5 43 - - +
l0-5 1 47 - - +
4h I Ih 24h 6h 24h 48h
5-FU 10-4 2 2 1 - - 0
10-3 3 3 10 - - 0
10-2 1 5 56 - - 0
24h 48h 72h 24h 48h 72h
DXM to-, 2 14 53 - - +
10-6 1 32 44 - + +
10-6 1 39 64 - + +
0-4 4 48 86 - + +
4h 24h 6h 12h 24h
VIN i0-9 1 7 - - -
10-8 1 85 - + +
10-7 2 99 - + +
10-6 2 98 - + +
'Pattern ofDNA degradation ofDNA agarose. Gels -, no DNAdegradation; +, DNA ladders;
0, smear of DNA.
somal DNA cleavage (Huschtscha et al., 1995). These data
demonstrate that 5-FU treatment of CCRF-CEM.f2 cells can
initiate apoptotic events but not lead to internucleosomal
DNA cleavage, which is characteristic of the later stages of
apoptosis. A recent study on several cell lines in which cell
death was induced by exposure to etoposide, serum depriva-
tion or reaching confluence reported the early appearance of
50kbp fragments detected using field inversion gel elect-
rophoresis. These fragments preceded the appearance of the
oligonucleosomal 180-200 bp DNA 'ladder' characteristic of
apoptosis (Oberhammer et al., 1993). One cell line, DU-145,
exhibited apoptotic morphology and 50 kbp DNA fragments
but no subsequent internucleosomal cleavage was observed.
It is possible that the DNA of 5-FU treated CCRF-CEM.f2
cells is cleaved initially into larger fragments, but whether
-this characterises the subpopulation of smaller cells adjacent
to the GI peak apparent after 24 h exposure is unknown
(data not shown).
Catchpoole and Stewart (1993) compared the apoptotic
process in CCRF-CEM.f2 and MOLT.4 cells after etoposide
exposure. Although there were many similarities in the
kinetics of etoposide effects, the apoptotic processes differed.
Both cell lines exhibited apoptotic morphology but DNA
fragmentation and apoptotic bodies were not evident in
MOLT.4 cells. These data together with our own emphasise
the importance of morphological criterion in assessing apop-
tosis while other methods such as DNA fragmentation and
flow cytometric analysis should be correlated with these
changes.
Our study shows that exposure of CCRF-CEM.f2 cells to
five anti-cancer drugs induced cell death by apoptosis,
although the kinetics varied for each drug. Some studies of
cytotoxic drug treated cells report necrotic patterns of cell
death but only one criterion was employed by some
(Vedeckis and Bradshaw, 1983; Dyson et al., 1986). Further-
more, drug concentration was also shown to affect the mode
of cell death (Lennon et al., 1991; Raffray and Cohen, 1991).
For instance, exposure of HL-60 cells to low concentrations
of several drugs induced cell death by apoptosis, while higher
concentrations caused necrotic cell death when assessed both
morphologically and by DNA gel electrophoresis (Lennon et
al., 1991; Hotz et al., 1992). The appearance of features of
a bDNA content Ssc
Drug-induced cell death
Li Huschtscha et al X
59
b
DNA content
U)
Ssc
Figure 5 Flow cytometry and forward light scatter (FSC) and side light scatter (SSC) plots of VIN-treated CCRF-CEM.f2 cells.
(a) 4h and (b) 18h.
cell death typical of apoptosis has been shown to vary ac-
cording to the time and concentration of drug exposure
(Kaufmann, 1989; Barry et al., 1990). Similarly, times of
appearance of DNA ladders on agarose gels varied between 2
and 48 h for etoposide-treated cells, depending on the cell
line studied (Kaufmann, 1989; Barry et al., 1990; Marks and
Fox, 1991). Variations in the time of appearance ofapoptotic
cells were also recorded after cytosine arabinoside treatment
(Kaufmann, 1989; Gunji et al., 1991). In our study the
apoptotic patterns of cell death appeared at similar times for
each drug at high concentrations. However, there was no
DNA cleavage detected on agarose gels 48 h after exposure
at the lowest concentrations of MTX (10-8 M) and FUdR
(4 x l08 M), despite extensive inhibition of growth and an
increase in the proportion of apoptotic nuclei detected
morphologically and by flow cytometry (Figures 2 and 3a-d;
Table I). It is feasible that at these low concentrations of
FUdR and MTX the apoptotic cascade was slowed. To
further elucidate the mechanisms of the apoptotic program
after drug exposure, studies using synchronised cell popula-
tions are needed.
The reason for the different kinetic patterns of apoptotic
induction in the one cell line with identical drug susceptibility
is not clear. However, there is evidence for more than one
pathway to induce apoptotis. Selvakumaran et al. (1994) also
showed a different rate of induction of apoptosis. In the case
where wild-type p53 gene accelerated apoptosis there was
shown to be down-regulation of bcl-2 expression, an inhibitor
of apoptosis, and up-regulation of 'bax' expression, a pro-
moter of apoptosis. TGF-13I induced apoptosis more slowly,
causing only reduced expression of bcl-2 thereby presumably
initiating the apoptotic process via another pathway.
The observation that anti-tumour drugs with disparate
modes of action induce cell death by apoptosis suggests that
it is not the drug-induced lesion that causes apoptotic cell
death but subsequent events such as disruption of growth
control signals. This view is supported by several studies
(Marks and Fox, 1991; Lowe et al., 1993). The first changes
seen after exposure of CCRF-CEM cells to etoposide were
double-stranded DNA breaks at 2 h followed by alterations
in the nucleotide pools (Marks and Fox, 1991). Apoptosis
was visible morphologically by 24 h and this was followed by
DNA internucleosomal cleavage which occurred by 48 h.
Further support for this concept comes from studies using
the bcl-2 oncogene. The expression of bct-2 suppressed apop-
tosis induced by cytotoxic drug treatment but the initial
biochemical effects still persisted (Fisher et al., 1993;
Kamesaki et al., 1993; Oliver et al., 1993; Walton et al.,
1993). For instance, FUdR exposure caused induction of
strand breaks, and reduced dTTP and thymidylate synthase
activity. These FUdR-induced changes were present in both
control and bcl-2 expressing cells yet the latter remained
viable, indicating that the bcl-2 gene acts downstream of the
initial lesion and before endonucleolytic cleavage of DNA
(Fisher et al., 1993).
Mutations in the tumour-suppressor gene p53 are found in
many tumours and tumour cell lines including CCRF-
CEM.f2 cells (Cheng and Haas, 1990). The p53 protein has
been shown to suppress cell cycle progression and induce cell
death by apoptosis (Lane, 1992). However despite the loss of
p53 function in CEM cells apoptosis still occurs. It seems
that only high drug concentrations induce the apoptotic pro-
cess in cells without p53 expression (Lowe et al., 1993).
Smets (1994), distinguishes physiological cell death by
apoptosis, which is internally programmed and under genetic
control, from pharmacological induced cell death. Drug-
induced cell death activates only the later stages of apoptosis
namely, DNA degradation and morphological changes.
Accumulating evidence now suggests that disruption of inte-
grated cell cycle events can act as a trigger to initiate the
apoptotic cascade (Kung et al., 1990; Askew et al., 1991;
Bissonette et al., 1992). The hypothesis, that disruption of the
normally regulated events of the cell cycle initiates apoptosis
can explain how drugs with disparate modes of action induce
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a common response. In fact, drug-damaged cells may activate
apoptosis and thereby eliminate those with irreparable DNA
damage, but the precise molecular signals that lead to the
initiation of this process are not yet understood. Our data
support this notion since four anti-cancer drugs caused cell
cycle perturbations before features of apoptosis were
identified. However, the observation that 5-FU induced mor-
phological apoptosis in CCRF-CEM.f2 cells that was not
accompanied by DNA cleavage provides a handle with which
to study the later molecular events in the apoptotic cascade.
The use of several criteria to assess cell death mechanisms
after exposure to various concentrations of DXM, MTX,
FUdR, 5-FU and VIN has provided some further insight
into the mechanism of cell death. The earliest changes
detected were cell cycle perturbations and these preceded the
appearance of apoptotic cell death in CCRF-CEM.f2 cells.
At the concentrations studied each drug caused its own
particular pattern of cell kill, though still recognisable as the
apoptotic process.
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